Discussion
The Multiple Myeloma Research Foundation (MMRF) has joined forces with the Dana Farber Cancer Institute to develop new biomarkers and treatments for people with smoldering multiple myeloma (SMM) —…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Discussion
The Multiple Myeloma Research Foundation (MMRF) has joined forces with the Dana Farber Cancer Institute to develop new biomarkers and treatments for people with smoldering multiple myeloma (SMM) —…
Discussion
Cevostamab (BFCR4350A), a bispecific antibody developed by Roche, induces durable and deep responses in heavily pre-treated patients with relapsed or refractory multiple…
Discussion
Antengene is asking health authorities in Singapore, Australia, and Hong Kong to approve Xpovio (selinexor) for the treatment of multiple myeloma, the company…
Discussion
The Dana-Farber Cancer Institute and Quest Diagnostics, the laboratory testing company, are conducting a study to measure the prevalence of COVID-19 among…
Discussion
The U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on a Phase 1 trial assessing Cellectis’ investigational CAR T-cell therapy,…
Discussion
Xgeva (denosumab) has been approved by the China National Medical Products Administration (NMPA) to prevent…
Don't have an account?
|
Already have an account?
Create your account by filling in the information below:
By creating an account, you are agreeing to the Privacy Policy and Terms of Service.